ENDXENoUS GR-HORMONE (GH) SECRETIOR AND RESPONSE TO METHIONINE-GH THERAPY IN G R W RETARDED CHILDREN.
In an open multi-center study 30 short prepubertal children (21 boys, 9 girls) were randmly divided into a treatment group (n=20) and a control group (n=10). Inclusion criteria were: age above 6 years; bone age below 8 "years" for girls and 10 "years" for boys; height SDS <-2.5; growth velocity <P25 for age or bone age; peak plasm GH in standard provocation tests >15 mU/1. In the treatment group endogenous GII-secretion was assessed by a 24-hour GH-profile, arginine infusion, exercise test, G I (1-29)-test and plasm SM-C/IGF-I. Met-GH was administered s.c. once a day in a dosage of 2 1u/m2 body surface. The integrated GI1 concentration over 24 hours (ICGfI) ranged between 2.2 and 13.4 mIU/I (median 5.6). In 58% of the children ICGH was <6 mIU/l (3ng/ml), the reported upper limit of "neurosecretory dysfunction". Mean (+ SD) growth velocities were: Baseline 0 -3m 3 -6 m 6 -9 m met-GH 4.4 2 1.5 8.2 5 2.3 6.6 2 2.0 6.5 2 2.2 control 4.5 + 0.8 4.4 + 1.4 3.8 + 2.1 4.0 + 1.4 12 Children had a growth response >2 cm/year. There were no significant correlations between the growth response versus ICGH and SM-C/IGF-I. Anti-GH antibodies were positive in 56% of the children at 9 months, in 4 of them with a high binding capacity. CONTlllBUTION OF NSE AND FWQUENCY TO TllE TLlEKAPEUlIC EFFECT OF Gll.
We treatcd 42 GI1 insufficient prcpubertal children aged 3-12 years u~t t > 12 i u biosynthetic GH per weck ior 1 year-after pretreatment observation o f 1 year. Group 1 (n=13) received 1, i u GH 3 days per weck, Group 2 ("~21) 2 i u GH 6 days per week and Group 3 ("4) 1 i u GI1 twice daily 6 days per week. Between groups, pretreatment age (CA), bone age (BA) and auxological parameters were identical.
Height velocity improved (p<0.001) i n a l l groups with a positive trend i n the higher frequency regimens. Changes i n height velocity (IN) SDS min for the 6 phase between 60-120 min. The metabolic clearance rate varied between 82-1 39 ml/min/ni2. 8 + 3 volunteers wzre given the s a w dose, 0.1 IU/kg BW, S.C. in the morning after 12 hours' fasting. They were resting in bed during the whole e m r i m n t , i.e. 12 hours. Lunch and dinner at 5 and 10 hours, respectively. Blccd samples every 15 min during the first 6 I?ours, every 30 m i n the next 2 hours and every 60 min during the remaining 4 hours. The peak GI Concentration, Cmax, was 53t4.2 mU/1 with tof 5.3i0.6 hours. After S.C. dosing the s e m concentration of GFI declined with a half-life of 248155 min. This half-life, considerably longer than the half-life found after i.v. aihninistration, probably reflects the absorption which thus is the rate limiting step in this way of administration. 
8SD a t s t a r t o f R) w i t h high Ab t l L r e s d~d n o t grow d u r~r i g t h c r a p y w~t h plt-GII. A f t e r 2 y w l t h o u t Rxand a d e c r e a s e o f Ab t l t r e s h e showed a tremendous y r o w t l i response t o t r e a t m e n t w l t h bio-met t i~o n y l -G H and o n l y a moderate r i s e o f Ab t l t r e s . The o l d e r boy B ( a g e 9.5 y , h e l g h t -7 . 8 9 ) w i t h low Ab t i t r e s showed a normal g r o w t h r a t e d u r~n g t r e a t m e n t w l t h p i t -G H and b i o -m e t h i o n y l -G H .

Growth d a t a & Ab s t u d l e s ( S c a t c l 1 a r d a n a l y s i s w~L l i pltGI1 MRC 661217) A GH t h e r a p y (Ulweek
U GH t h e r a p y (Ulwe d u r a t i o n o f R, ( y , h e l y h t v e l o c i t y (cml!
Ab t l t r e s 1 .
rclevant to the response to treatment with 611, but pretreatment IIVSDS i s the h c a t c h a r d a n a l y s i s with bio-methionyl-GI4 showed a l o w e r b i n d l n g dominant factor i n predicting i t s aagnitude. C a p a c i t y . T h i s , and t h e l e s s e r a n t l g e n l c i t y o f blo-GH ma e x p l a i n t h e t t i e r a p e u t i c a l success i n t h e s e 2 p a t i e n t s with IGHD b e IA. 
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H o p i t 3 1 S a i n t -V i n c e n t de P a u l , 75014 P a r i s , F r a n c e . ISOLATED GROWTH HORMONE DEFICIENCY. Slxtcen p n t l c n t s (15m,l T) LVILII (jrowtti l~o r n i o n e (C I l l (IDl~c~e n c y i %~c r c Lrcalerl w l t l l m c l h~o i i y l G I I (Somnl.rcm, I i l l y ) I'or one yr:~r I n i s o l a t e d GH d e f i c i e n c y , a t o o i n s u f f i c i e n t h e i g h t a t o n s e t a f t e r previous Lliempy i v l l l i p11.1~1Lnry GII. ~l e n r i rlurol.~on 111 L r e a t l~i e r~t o f a puberty l e a d s to reduced a d u l t h e i g h t , ln order to p r e v e n t w~t h pituiLary C I I was 5,513.3 yrs (x2SD), tliin LrcnLrncril. was lntc:~.riiliLr:C t h i s we have t r i e d t h e efficiency o f LHRH anal ague in a s s o c i a t l n n f o r 0,4 y r s on ;,vernqc b e f o r e onset o f Sornntrem Lliern[,y. AL t t i x t~r n c w i t h GH in such cases, c1ironr1loq~r:il nrje was 15,1+5,l? -yrs, 11oric aqe wn:; 12,3+2,7 yrs an11 t~clcllit w:~:; -2,8+1,1 SD. Som:~l.rem dose w;l :; fl,l6U/kq 1.m. 3 L~i n c s weekly. T l~c L o n g -a c t i n g T r p 6 LHRH analogue (LHRHa) was used i n 4 male proLnc11l was approvcrt by L I~C r:tli~r;il r n m lnlLLcu :~ncl i r~f o r m e c l crlrlsrrlt p a t i e n t s aged 12 t o 16 y e a r s , t r e a t e d w i t h hGH 20 I U l k g l y r from was o b t a~n c d . GrowLh . clccrense from onset t o I, months o f therapy and n o sample was cvalunThough p r e l i m i n a r y , t h e s e r e s u l t s seem e n c o u r a g i n g . t c d as poslt lve; tiowever, one p n t l e n t w l i h a l l e r q l r r!lathes~5 d c v e l r~l~e c l Treatlllent w i t h LHRHa a1 1 owed ma j n t e n a n c e o f plasma t e s t o s t e r o n e lncrcnsinq titers b u t r c n l l n~~e d t o qrow well. No pal lcril dcvelopcd siqrlla t p r e -p u b e r t a l l e v e l s , Since c o n t r o l s t u d i e s i n p u b e r t 3 1 ricont r . c o l l pnlyprrlLlc!c-arltlhllr:;. I n conclusion, Son1;lLrem i s crllllpop a t i e n t s w i t h i s 0 1 a t e * GH d e f i c i e n c y t r e a t e d w i t h hGH a l o n e t c n t l o p l l u l t n r y G 11 I n 11:; rjrrlwLh ~l r~l m o~l n c ] nrLlon. Ill crlnlrnst I r 1 showed an i n s u f f i c i e n t g r o w t h s p u r t , i t i s 1 i k e l y t h a t t h e . . ,.
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